Glenmark Pharmaceuticals Limited Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹2286.9Market Cap
₹ 63,086 Cr.Stock P/E
21.4ROE
30.5 %RSI
55.33Trend
BullishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
Glenmark Pharmaceuticals Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest Glenmark Pharmaceuticals Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the Glenmark Pharmaceuticals Ltd share price chart currently indicates a Bullish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 2286.9 |
| RSI (14) | 55.33 |
| 50 DMA | 2246.37 |
| 200 DMA | 2085.92 |
| Trend | Bullish |
| A/D Rating | C |
| RS Rating | 61 |
| EPS Rating | 17 |
| TI65 | 1.01 |
| TI65 Trend | Neutral |
Pivot Points Analysis
Daily pivot points for Glenmark Pharmaceuticals Limited calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹2339.46 |
| R2 | ₹2326.23 |
| R1 | ₹2306.56 |
| PP | ₹2293.33 |
| S1 | ₹2273.66 |
| S2 | ₹2260.43 |
| S3 | ₹2240.76 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 63,086 Cr. |
| Current Price | ₹ 2,236 |
| High / Low | ₹ 2,474 / 1,793 |
| Stock P/E | 21.4 |
| Book Value | ₹ 372 |
| Dividend Yield | 0.11 % |
| ROCE | 39.8 % |
| ROE | 30.5 % |
| Face Value | ₹ 1.00 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 3,001 | -403 | 13% |
| Jun 2023 | 3,036 | 173 | 14% |
| Sep 2023 | 3,207 | -62 | 14% |
| Dec 2023 | 2,507 | -331 | -8% |
| Mar 2024 | 3,063 | -1,214 | 16% |
| Jun 2024 | 3,244 | 340 | 18% |
| Sep 2024 | 3,434 | 354 | 18% |
| Dec 2024 | 3,388 | 348 | 18% |
| Mar 2025 | 3,256 | 4 | 17% |
| Jun 2025 | 3,264 | 47 | 18% |
| Sep 2025 | 6,047 | 610 | 39% |
| Dec 2025 | 3,901 | 403 | 22% |
| Mar 2026 | 3,771 | 301 | 20% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 46.50% |
| FIIs | 34.78% |
| DIIs | 6.02% |
| Government | 0.00% |
| Public | 12.69% |
| No. of Shareholders | 88,103 |
Pros and Cons
Pros
- Healthy return on equity of 30.5% indicating strong capital allocation efficiency.
- Strong technical momentum with price holding comfortably above the 50 DMA (2246.37).
Cons
Related NSE Stocks
Dr. Reddy's Laboratories Limited
View Share Price Analysis →JBM Auto Limited
View Share Price Analysis →Allied Blenders and Distillers Limited
View Share Price Analysis →Whirlpool of India Limited
View Share Price Analysis →Netweb Technologies India Limited
View Share Price Analysis →Power Grid Corporation of India Limited
View Share Price Analysis →Intellect Design Arena Limited
View Share Price Analysis →Thermax Limited
View Share Price Analysis →Godrej Industries Limited
View Share Price Analysis →Bajaj Housing Finance Limited
View Share Price Analysis →Granules India Limited
View Share Price Analysis →Persistent Systems Limited
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for Glenmark Pharmaceuticals Ltd share?
Based on the latest closing data, the technical momentum for Glenmark Pharmaceuticals Ltd is currently evaluated as Bullish. The stock is exhibiting an RSI (14) of 55.33, indicating it is trading in a neutral balanced zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (2246.37) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for Glenmark Pharmaceuticals Ltd?
According to Classic Pivot Point methodologies, the core trading floor for Glenmark Pharmaceuticals Ltd today centers at a Pivot Point (PP) of ₹2293.33. Upside resistance challenges are calculated at R1: ₹2306.56, R2: ₹2326.23, and R3: ₹2339.46. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹2273.66, S2: ₹2260.43, and S3: ₹2240.76.
How does the fundamental ROE and P/E ratio look for Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd is currently trading with a valuation metrics context of a Stock P/E of 21.4, against a core structural efficiency Return on Equity (ROE) standing at 30.5 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 17, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell Glenmark Pharmaceuticals Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Speculative Momentum Phase (Neutral / Hold). Glenmark Pharmaceuticals Ltd is tra... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of C, a Relative Strength (RS) ranking of 61, and long-term trend backing from the TI65 indicator (Neutral pattern).